argenx SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Analysts

argenx SE (NASDAQ:ARGX) has received a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $596.78.

ARGX has been the topic of a number of research analyst reports. Baird R W cut shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company lifted their price target on shares of argenx from $547.00 to $639.00 and gave the stock an “overweight” rating in a report on Friday. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a report on Friday. Evercore ISI boosted their target price on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. Finally, Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and upped their price target for the company from $515.00 to $650.00 in a research report on Friday.

argenx Trading Up 1.6 %

Shares of ARGX opened at $595.58 on Friday. The stock has a 50 day moving average of $539.46 and a 200 day moving average of $465.81. argenx has a 12 month low of $327.73 and a 12 month high of $610.73. The company has a market capitalization of $35.61 billion, a price-to-earnings ratio of -676.80 and a beta of 0.63.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same period in the previous year, the business posted ($1.25) EPS. As a group, equities research analysts predict that argenx will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARGX. Profund Advisors LLC raised its position in shares of argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after buying an additional 28 shares in the last quarter. Wealth Alliance increased its stake in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after acquiring an additional 29 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after acquiring an additional 40 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after acquiring an additional 43 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its holdings in shares of argenx by 3.1% during the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock worth $737,000 after purchasing an additional 52 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.